Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$11.0 million.

  • Aclaris Therapeutics' Free Cash Flow fell 14979.55% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.0 million, marking a year-over-year decrease of 13297.4%. This contributed to the annual value of -$20.2 million for FY2024, which is 7463.9% up from last year.
  • Aclaris Therapeutics' Free Cash Flow amounted to -$11.0 million in Q3 2025, which was down 14979.55% from -$10.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Free Cash Flow ranged from a high of $22.0 million in Q3 2024 and a low of -$26.9 million during Q1 2023
  • Moreover, its 5-year median value for Free Cash Flow was -$12.3 million (2024), whereas its average is -$13.4 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Free Cash Flow crashed by 20928.83% in 2023, and later surged by 18928.21% in 2024.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Free Cash Flow stood at -$17.3 million in 2021, then decreased by 11.26% to -$19.2 million in 2022, then skyrocketed by 62.53% to -$7.2 million in 2023, then dropped by 24.1% to -$8.9 million in 2024, then dropped by 22.57% to -$11.0 million in 2025.
  • Its Free Cash Flow was -$11.0 million in Q3 2025, compared to -$10.0 million in Q2 2025 and -$13.1 million in Q1 2025.